- Trials with a EudraCT protocol (24)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (89)
24 result(s) found for: RICE.
Displaying page 1 of 2.
EudraCT Number: 2016-000259-28 | Sponsor Protocol Number: 54179060LYM3003 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma. | |||||||||||||
Medical condition: Mature B-Cell Neoplasm | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) BE (Completed) CZ (Completed) HU (Completed) DE (Completed) NL (Completed) ES (Completed) PL (Completed) BG (Completed) Outside EU/EEA SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001468-39 | Sponsor Protocol Number: GS-US-313-1090 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:Gilead Sciences, Inc. | ||||||||||||||||||
Full Title: Phase 1b trial evaluating idelalisib in children and adolescents with relapsed or refractory diffuse large B-cell lymphoma or mediastinal B-cell lymphoma in combination with RICE | ||||||||||||||||||
Medical condition: B-cell malignancies | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-011571-71 | Sponsor Protocol Number: VOPO-P-307 | Start Date*: 2009-07-20 |
Sponsor Name:Novartis Consumer Health SA | ||
Full Title: A randomized, double-blind, multi-center, placebo-controlled, 3-treatment arm, parallel group study to evaluate the efficacy and safety of diclofenac diethylamine 2.32% gel applied twice or three t... | ||
Medical condition: ankle sprain Grade I or II | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-003797-25 | Sponsor Protocol Number: VOPO-PE-201 | Start Date*: 2007-10-24 | |||||||||||
Sponsor Name:Novartis Consumer Health SA | |||||||||||||
Full Title: A randomized, double-blind, multi-center, vehicle-controlled, parallel group study to evaluate the efficacy and safety of diclofenac diethylamine 2.32% gel applied once or twice daily in subjects w... | |||||||||||||
Medical condition: acute ankle sprain | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003048-22 | Sponsor Protocol Number: Uni-Koeln-3571 | Start Date*: 2020-06-16 | |||||||||||
Sponsor Name:Universität zu Köln | |||||||||||||
Full Title: A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal... | |||||||||||||
Medical condition: locally advanced esophageal adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004037-17 | Sponsor Protocol Number: 19_RIPH1_07 | Start Date*: 2021-07-28 | ||||||||||||||||
Sponsor Name:Centre Hospitalier Universitaire de Martinique | ||||||||||||||||||
Full Title: Multicenter, randomized, open-label non-inferiority trial, comparing two antibiotic therapy periods (3 versus 7 days) in patients with mild leptospirosis and seen at the hospital in 5 French overse... | ||||||||||||||||||
Medical condition: Mild Leptospirosis : defined as Leptospirosis without the following severity criteria : a. Hemodynamic failure* with onset of septic shock b. Hematologic failure* with hemoglobin requiring red blo... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000465-37 | Sponsor Protocol Number: 0524A-082 | Start Date*: 2008-05-30 | |||||||||||
Sponsor Name:Laboratoires Merck Sharp & Dohme - Chibret | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Ther... | |||||||||||||
Medical condition: Dyslipidemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002503-33 | Sponsor Protocol Number: GC 2005 04 | Start Date*: 2006-06-23 |
Sponsor Name:Our Lady's Hospital for Sick Children | ||
Full Title: PROTOCOL FOR THE TREATMENT OF EXTRACRANIAL GERM CELL TUMOURS IN CHILDREN AND ADOLESCENTS (GC III) | ||
Medical condition: Extracranial germ cell tumours | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002773-10 | Sponsor Protocol Number: IRFMN-LUNG-8287 | Start Date*: 2022-03-14 | ||||||||||||||||
Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI | ||||||||||||||||||
Full Title: A phase III prevention trial of canakinumab in subjects at high risk for lung cancer | ||||||||||||||||||
Medical condition: Subjects at high risk for lung cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-005112-17 | Sponsor Protocol Number: IRFMN-BRC-7103 | Start Date*: 2017-07-11 | |||||||||||
Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI | |||||||||||||
Full Title: Multicenter, randomized, phase II study of neoadjuvant chemotherapy associated or not with zoledronate and atorvastatin in triple negative breast cancers - YAPPETIZER Study | |||||||||||||
Medical condition: Triple Negative Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001856-36 | Sponsor Protocol Number: RF-2016-02362383 | Start Date*: 2018-08-07 | |||||||||||
Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI | |||||||||||||
Full Title: A RANDOMIZED PHASE 2 CLINICAL TRIAL TO EVALUATE THE ACTIVITY OF ATRA IN COMBINATION WITH ANASTROZOLE IN PRE-OPERATIVE PHASE OF OPERABLE HR-POSITIVE/HER2-NEGATIVE EARLY BREAST CANCER EBC ATRA TRIAL | |||||||||||||
Medical condition: Patients with newly, untreated, resectable HR+/HER2- eBCs, suitable for pre-operative therapy with anastrozole | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001271-38 | Sponsor Protocol Number: LT 2004 09 | Start Date*: 2006-06-23 |
Sponsor Name:Our Lady's Hospital for Sick Children | ||
Full Title: Intensified pre-operative chemotherapy and radical surgery for HIGH RISK HEPATOBLASTOMA SIOPEL 4 | ||
Medical condition: Hepatoblastoma | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: IE (Completed) BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001103-23 | Sponsor Protocol Number: PA0008 | Start Date*: 2016-11-21 | |||||||||||
Sponsor Name:UCB Biopharma SPRL | |||||||||||||
Full Title: A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ACTIVE PSORIATIC ARTHRITIS | |||||||||||||
Medical condition: psoriatic arthritic | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001518-39 | Sponsor Protocol Number: K-877-303 | Start Date*: 2017-01-16 | |||||||||||
Sponsor Name:Kowa Research Institute, Inc. | |||||||||||||
Full Title: A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With a 40-Week, Active-Controlled, Open-Label Extension to Evaluate the Efficacy and Safety of K-877 in Adult Pa... | |||||||||||||
Medical condition: Severe hypertriglyceridemia [fasting TG levels >=500 mg/dL (5.65 mmol/L) and <2000 mg/dL (22.60 mmol/L) and mild or moderate renal impairment. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) PL (Completed) BG (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003511-37 | Sponsor Protocol Number: K-877-301 | Start Date*: 2017-01-16 | |||||||||||
Sponsor Name:Kowa Research Institute, Inc. | |||||||||||||
Full Title: A Phase 3, Multi-Center, Placebo-Controlled, Randomized, DoubleBlind, 12-Week Study With a 40-Week, Active-Controlled, DoubleBlind Extension to Evaluate the Efficacy and Safety of K-877 in Adult ... | |||||||||||||
Medical condition: severe hypertriglyceridemia [fasting TG levels >=500 mg/dL (5.65 mmol/L) and <2000 mg/dL (22.60 mmol/L) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005377-29 | Sponsor Protocol Number: CNS 2004 03 | Start Date*: 2006-05-03 |
Sponsor Name:Dept of Pediatrics, University Hospital of North Norway | ||
Full Title: SIOP-LGG 2004 Cooperative multicenter Study for Children and Adolescents with Low Grade Gliome | ||
Medical condition: Low Grade Glioma | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NO (Ongoing) IE (Completed) GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-001558-27 | Sponsor Protocol Number: SP847 | Start Date*: 2012-06-07 | |||||||||||
Sponsor Name:UCB BIOSCIENCES, Inc | |||||||||||||
Full Title: A MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF LACOSAMIDE (LCM) ORAL SOLUTION (SYRUP) AS ADJUNCTIVE THERAPY IN CHILDREN WITH PARTIAL ONSET SEIZURES | |||||||||||||
Medical condition: Epilepsy, partial onset seizures | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001139-31 | Sponsor Protocol Number: STS 2005 14 | Start Date*: 2006-01-27 |
Sponsor Name:Research and Development Directorate, University Hospitals of Leicester NMS Trust | ||
Full Title: European Paediatric Soft Tissue Sarcoma Study Group protocol for Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas 2005 | ||
Medical condition: Non-rhabdomyosarcoma soft tissue sarcoma. The so called “non-rhabdomyosarcoma” soft tissue sarcomas (NRSTS) account for about 3-4% of paediatric cancers and constitute a very heterogeneous group ... | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) IT (Ongoing) BE (Completed) IE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001446-18 | Sponsor Protocol Number: SP0966 | Start Date*: 2014-02-11 | |||||||||||
Sponsor Name:UCB Biosciences Inc. | |||||||||||||
Full Title: A MULTI-CENTER, OPEN-LABEL, EXPLORATORY STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS ≥1 MONTH TO <18 YEARS WITH EPILEPSY SYNDROMES ASSOCIATED WITH GE... | |||||||||||||
Medical condition: Epilepsy | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) PL (Completed) Outside EU/EEA FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002402-21 | Sponsor Protocol Number: RG_09-205 | Start Date*: 2007-08-24 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate in reducing ototoxicity in patients receiving cisplatin chemotherapy for standard risk hepatoblastoma | |||||||||||||
Medical condition: Standard risk hepatoblatoma in children | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) FR (Ongoing) IE (Completed) ES (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
